Wed, Dec 17, 2014, 6:32 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fudfighter4 fudfighter4 Jul 6, 2013 1:51 PM Flag

    If you wait for the robins Spring will be over

    Now that the risk/reward profile of INSM has been transformed by the successful outcome of the Arikace EU Phase III clinical trial - and the data from the additional nine-month toxicity study requested by the FDA suggest no safety risk with prolonged use - one would expect substantial accumulation over the next six months or so.

    The price just after Phase III results are released is often just the start -

    Date ...............Open ... High ... Low ...Close ... Volume

    12/23/2009 - 30.85 - 31.40 - 30.55 - 30.75 - 4,746,144
    12/16/2009 - 28.30 - 28.66 - 27.96 - 28.33 - 2,796,200
    12/09/2009 - 27.51 - 27.69 - 26.76 - 27.11 - 3,555,438
    12/02/2009 - 26.83 - 27.56 - 26.78 - 27.46 - 3,564,268

    11/25/2009 - 28.08 - 28.20 - 27.47 - 27.96 - 2,669,918
    11/18/2009 - 28.50 - 28.70 - 27.77 - 27.84 - 4,661,150
    11/11/2009 - 28.80 - 29.48 - 28.24 - 28.51 - 4,908,632
    11/04/2009 - 27.61 - 28.19 - 26.24 - 26.48 - 12,487,950

    10/28/2009 - 19.30 - 19.37 - 17.83 - 18.01 - 8,588,417
    10/21/2009 - 19.83 - 20.40 - 18.94 - 19.08 - 7,083,437
    10/14/2009 - 19.03 - 19.22 - 18.82 - 19.16 - 7,077,614
    10/07/2009 - 19.45 - 19.65 - 18.64 - 18.96 - 4,982,780

    09/30/2009 - 19.11 - 19.26 - 18.51 - 18.82 - 5,144,892
    09/23/2009 - 19.50 - 19.54 - 18.80 - 18.87 - 4,692,131
    09/16/2009 - 20.04 - 20.30 - 19.77 - 19.90 - 4,546,353
    09/09/2009 - 19.49 - 19.75 - 19.26 - 19.61 - 5,215,776
    09/02/2009 - 18.47 - 18.56 - 17.36 - 17.46 - 10,211,830

    08/26/2009 - 22.00 - 22.78 - 19.42 - 20.50 - 39,614,900
    08/19/2009 - 15.25 - 15.95 - 15.25 - 15.86 - 5,616,838
    08/12/2009 - 15.85 - 16.50 - 15.76 - 16.21 - 8,721,898
    08/05/2009 - 15.16 - 15.18 - 14.58 - 14.90 - 6,429,720

    07/29/2009 - 14.32 - 15.45 - 14.15 - 14.71 - 29,962,190
    07/22/2009 - 14.50 - 14.83 - 13.35 - 14.05 - 33,920,750

    [July 20, 2009 - Human Genome Sciences, Inc. ... today announced that BENLYSTA™ ... met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).]

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Loan me a Mil -I want to buy ---

      Sentiment: Strong Buy

    • I bought more under 10 last week. I really didn't think that price would still be available. I hope this stays under the radar a little longer for my sake.

      • 4 Replies to x10bagger
      • insmd is on the most up board---LOL

        Sentiment: Strong Buy

      • I suggested yesterday that there wouldn't be many more shares for sale than are currently becoming available if the share price was increased by 50%.

        And as long as the share price isn't going up - why would anybody buy now rather than later?

        But the longer the investors monitoring the situation delay their accumulation, the shorter the period in which they will all eventually be buying shares - from investors who will have even less reason to sell than they do now.

      • Guess we're in a temporary expectation-management phase - with the aim of ensuring that when the main post-results accumulation phase does kick off, retail investors will have sufficient doubt to prevent them from starting to buy until the price has moved significantly higher than $10.

        "Nothing happening here any time soon - move along please".

      • My gut feeling is that the majority of the shares sold since the Phase III results were released have been snapped up by retail investors who understand valuation.

        I wouldn't be at all surprised to find that the sellers have been professional investors with the objective of nipping in the bud any momentum in price appreciation - and that they agreed before the results were released to mislead retail investors by dropping the price as though the results were bad news.

        The Short position at the end of June will give us an idea of how many shares the Shorts supplied to the tracker funds having already been tipped off that the results would allow flexibility for negative spin.

 
INSM
14.37+0.67(+4.89%)Dec 17 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.